Advanced search
Publication Cover
Journal of Chemotherapy Volume 18, 2006 - Issue 2
Submit an article Journal homepage
26
Views
8
CrossRef citations to date
0
Altmetric
Antimicrobial Chemotherapy

In Vitro Bactericidal Activity of Oxazolidinone, RBx 8700 against Mycobacterium tuberculosis and Mycobacterium avium complex

M. Rao
,
R. Sood
,
S. Malhotra
,
T. Fatma
,
D.J. Upadhyay
&
A. Rattan
Pages 144-150 | Published online: 18 Jul 2013

References

  • Snider DE. Tuberculosis: the world situation. History of the disease and efforts to combat it. in Tuberculosis: Back to the future. Hs. Porter JDH, McAdam KPWJ Wiley and Sons Ltd. (1994); Pages 14-31.
  • Rattan A, Kalia A, Ahmad N. Multidrug-resistant Mycobacterium tuberculosis: Mol Persp Emerg Infect Dis. 1998; 4 (2), 195–209.
  • Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams B. G. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis. 2002; 185, 1197–1202.
  • De Cock KM, Soro B, Coulibaly IM, Lucas SB. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 1992; 268: 1581–1587.
  • Khasnobis S, Escuyer VE, Chatterjee D. Emerging ther-apeutic targets in tuberculosis: post-genomic era. Expert Opin Ther Targets. 2002; 6 (1): 21–40.
  • Eustice DC, Felman GM, Zajac I, Slea AM. Mechanism of action of DuP 721: inhibition of an early event during initi-ation of protein synthesis. Antimicrob. Agents Chemother. 1997; 41: 2127–2131.
  • Zurenko GE, Yagi BH, Schhadt RD et al. In vitro activ-ities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40 (4): 839-845.
  • Alcala L, Ruiz-Serrano MJ, Fernandez-Turegano CP et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother. 2003; 47 (1): 416-417.
  • Cyanamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother. 1999; 43 (5): 1189–1191.
  • Sood R, Rao M, Singhal S, Rattan A. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages. Intern. J Antimicrob Agents. 2005; 25 (6): 464–468.
  • Tentative Standard. Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes, Second Edition. National Committee for Clinical and Laboratory Standards, Villanova, Pa. 2000.
  • Sood R, Rao M, Malhotra S, et al. RBx 8700, a novel oxazolidinone against community acquired respiratory tract infections. Washington DC, Oct. 30-Nov 2, 2004, 44th ICAAC poster session, F-1414.
  • Rastogi N, Goh SK, Berchel M, Bryskier A. In vitro activities of the ketolides telithromycin (HMR 3647)and HMR 3004 compared to those clarithromycin against slowly grow-ing mycobacteria at pHs 6.8 and 7.4. Antimicrob Agents Chemother. 2000; 44: 2848–2852.
  • Cercenado E, Garrote F, Souza E. In vitro activity of linezolid against multiple resistant gram-positive clinical iso-lates. J Antimicrob Chemother. 2001; 47: 77–81.
  • Jones RN, Johnson DM, Erwin ME. In vitro antimicro-bial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother. 1996; 40 (3): 720–726.
  • Craig WA. Does the dose matter? Clin.Infect Dis. 2001; 33: S233–S237.
  • Lode HK, Borner K, Koeppe P. Pharmacodyanamics of quinolones. Clin Infect Dis. 1998; 27: 33–39.
  • Lacy MK, Nicolau DP, Nightingale CH, Quintillani R. The pharmacodyanamics of aminoglycosides. Clin Infect Dis. 1998; 27: 23–27.
  • Ondes D, Van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodyanomics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother. 2002; 46 (11): 3486–3489.
  • Pletz WR, Roux AD, Roth A, Newmann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective randomized study. Antimicrob Agents Chemother 2004; 48: 780–782.
  • Herbert D. Paramasivan CN, Venkatesan P, Kubendiran G, Prabhakar R and Mitchison DA. Bactericicdal action of ofloxacin, sulbactam-ampicillin, rifampin and isoni-azid on the logarithmic and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40 (10): 2296-2299.
  • Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison DA. Bactericidal action of gati-floxacin, rifampin, and isoniazid on logarithmic- and station-ary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49 (2): 627–631.
  • Mitchison DA. The search for the new sterilizing anti-tuberculosis drugs. Frontiers Bioscience 2004; 9: 1059–1072.
  • Mitchison DA. The Garrod lecture. Understanding the chemotherapy of tuberculosis-current problems. J Antimicrob Chemother 1992; 29: 477–493.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.